Back to Search Start Over

Adapter CARs: Estimation of the affinity between adapter and CAR domain required for function

Authors :
Bartsch, T.
(0000-0002-1285-5052) Arndt, C.
González Soto, K. E.
(0000-0001-7462-7111) Wodtke, R.
(0000-0001-7711-4805) Brandt, F.
Loureiro, L. R.
Mitwasi, N.
Kegler, A.
(0000-0001-5099-2448) Feldmann, A.
(0000-0002-8029-5755) Bachmann, M.
Bartsch, T.
(0000-0002-1285-5052) Arndt, C.
González Soto, K. E.
(0000-0001-7462-7111) Wodtke, R.
(0000-0001-7711-4805) Brandt, F.
Loureiro, L. R.
Mitwasi, N.
Kegler, A.
(0000-0001-5099-2448) Feldmann, A.
(0000-0002-8029-5755) Bachmann, M.
Source :
TUMOR IMMUNOLOGY MEETS ONCOLOGY (TIMO) XVI 2022 HALLE, 07.-09.07.2022, Halle, Deutschland
Publication Year :
2022

Abstract

As next generation for CAR T cells, adaptor CAR platforms have been developed, which are designed to improve safety, but at the same time maintain the high efficiency of the CAR T cell approach. In our lab, we developed the UniCAR system, which consists of universal (Uni)CAR T cells and tumor-specific target modules (TMs), which work as bridging molecules between the UniCAR T cells and the target cells. Until now, type 1 and type 2 UniCARs were developed. Both UniCAR types consist of an extracellular binding domain derived from a monoclonal antibody (mAb) directed to the nuclear La/SS-B protein. Type 1 UniCARs are derived from the anti-La mAb 5B9. Type 2 UniCARs from the anti-La mAb 7B6. As both anti-La mAbs are not able to precipitate native La protein, both anti-La mAbs are directed to a specific cryptic epitope which is not accessible on the cell surface. Thus, the UniCAR T cell is per se inert. To activate the UniCAR T cell for tumor cell killing a TM is needed as a second component. Typically, a TM is composed of a tumor-specific binding domain and the respective La epitope. Consequently, the affinity of the TM towards the target antigen but also towards the UniCAR T cell via the E5B9-tag plays an important role for functionality of the respective UniCAR system. In this study, we representatively aimed to elucidate if and how the affinity of the type 1 UniCAR domain to the E5B9 epitope impacts the functionality of the UniCAR system. To alter the interaction of UniCAR and TM, we designed different mutated E5B9 peptides (M1-M3) carrying one or two amino acid (aa) changes. In detail, aspartic acid and/or glutamic acid were mutated to glycine residues as they most probably are involved in epitope/paratope interactions. We subsequently fused these mutated peptides to an scFv domain, resulting in three different mutated TM versions. By conducting ELISA and flow-cytometry based binding studies, we showed that a single aa exchange (D3>G3) in M1 did not alter the affini

Details

Database :
OAIster
Journal :
TUMOR IMMUNOLOGY MEETS ONCOLOGY (TIMO) XVI 2022 HALLE, 07.-09.07.2022, Halle, Deutschland
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1415608616
Document Type :
Electronic Resource